Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Chinese Patent Office
AstraZeneca
Julphar
McKinsey
US Department of Justice
Accenture
Moodys
Mallinckrodt

Generated: December 10, 2018

DrugPatentWatch Database Preview

ERIVEDGE Drug Profile

« Back to Dashboard

When do Erivedge patents expire, and when can generic versions of Erivedge launch?

Erivedge is a drug marketed by Genentech and is included in one NDA. There are two patents protecting this drug.

This drug has forty-three patent family members in twenty-two countries.

The generic ingredient in ERIVEDGE is vismodegib. One supplier is listed for this compound. Additional details are available on the vismodegib profile page.

Drug patent expirations by year for ERIVEDGE
Generic Entry Opportunity Date for ERIVEDGE
Generic Entry Date for ERIVEDGE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ERIVEDGE
Synonyms for ERIVEDGE
085G559
2-Chloranyl-~{n}-(4-Chloranyl-3-Pyridin-2-Yl-Phenyl)-4-Methylsulfonyl-Benzamide
2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)benzamide
2-Chloro-N-(4-chloro-3-(2-pyridl)phenyl)-4-(methylsulfonyl)benzamide
2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methyl sulfonyl)benzamide
2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide
2-chloro-N-(4-chloro-3-pyridin-2-yl-phenyl)-4-methanesulfonyl-benzamide
2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide
2-CHLORO-N-[4-CHLORO-3-(2-PYRIDINYL)PHENYL]-4-(METHYLSULFONYL)-BENZAMIDE
2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide
2-chloro-N-[4-chloro-3-(2-pyridyl)phenyl]-4-methylsulfonyl-benzamide
2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide
2-chloro-N~1~-[4-chloro-3-(2-pyridyl)phenyl]-4-(methylsulfonyl)benzamide
25X868M3DS
4CA-1325
879085-55-9
A10467
AB0008125
AB01565813_02
ABP000894
AC-26969
AJ-103831
AK-77261
AKOS015966534
AN-471
ANW-60962
AOB1040
AS-14066
AX8167197
BC660083
BCP9000713
BCPP000223
BDBM50249522
Benzamide, 2-chloro-N-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)-
BENZAMIDE, 2-CHLORO-N-[4-CHLORO-3-(2-PYRIDINYL)PHENYL]-4-(METHYLSULFONYL)-
BG0661
BPQMGSKTAYIVFO-UHFFFAOYSA-N
C19H14Cl2N2O3S
C538724000
CHEBI:66903
CHEMBL473417
CS-0255
CTK8B8648
CUR-691
D03EDQ
D09992
D0LB7J
DB08828
DTXSID40236689
Erivedge (TN)
FT-0675833
GD 0449|||2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide
GDC 0449
GDC-0449
GDC-0449 - Selumetinib
GDC-0449 (Vismodegib)
GDC-0449, GDC0449, GDC 0449, 879085-55-9
GDC-0449,Vismodegib
GDC-0449,Vismodegib, HhAntag691
GDC-0449(Vismodegib)
GDC-0449(Vismodegib)/GDC0449
GDC-449
GDC0449
GTPL6975
HE067811
HE401106
Hh-Antag691
HhAntag691
HMS3604K16
HMS3654E17
HSDB 8130
HY-10440
J-509076
J90022
KB-308771
KB-81450
KS-000000BH
MCULE-6680076172
MFCD12407408
MLS006012035
MolPort-009-679-417
NCGC00242497-01
NCGC00242497-02
NSC 747691
NSC-747691
NSC-755986
NSC747691
NSC755986
PB15086
PubChem19137
Q-2305
QCR-40
R 3616
R-3616
RG-3616
RG3616
RL05479
s1082
SC-87729
SCHEMBL302587
SMR004703564
SR-01000941574
SR-01000941574-1
ST24040458
TC-149707
UNII-25X868M3DS
V-4050
VIS
Vismodegib
Vismodegib (GDC-0449)
Vismodegib (SHH inhibitor)
Vismodegib (USAN/INN)
Vismodegib [USAN:INN]
Vismodegib, free base
vismodegibum
X4669
ZINC40899447

US Patents and Regulatory Information for ERIVEDGE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genentech ERIVEDGE vismodegib CAPSULE;ORAL 203388-001 Jan 30, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Genentech ERIVEDGE vismodegib CAPSULE;ORAL 203388-001 Jan 30, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for ERIVEDGE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013 00050 Denmark ➤ Sign Up PRODUCT NAME: VISMODEGIB; NAT. REG. NO/DATE: EU71/13/848 20130712; FIRST REG. NO/DATE: CH 62497 20130530
90057-6 Sweden ➤ Sign Up PRODUCT NAME: VISMODEGIB OCH SOLVAT DAERAV; NAT. REG. NO/DATE: EU/1/13/848 20130712; FIRST REG.: CH IKS-NR 62497 20130530
2013024 Lithuania ➤ Sign Up PRODUCT NAME: VISMODEGIBUM; NAT. REGISTRATION NO/DATE: SWISS 62497 01 20130530; FIRST REGISTRATION: EU/1/13/848 20130712
278 Luxembourg ➤ Sign Up PRODUCT NAME: VISMODEGIB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES(ERIVEDGE)
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Mallinckrodt
AstraZeneca
Farmers Insurance
Cipla
Healthtrust
Chinese Patent Office
Cantor Fitzgerald
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.